NASDAQ · ELTX
Healthcare · Biotechnology
$1.68
Down-$0.07 (-4.00%)
Updated Nov 2, 2026, 2:08 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ELTX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ELTX closed at $1.68 after 20 trading sessions, down 12.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $1.74 | $1.78 | $1.655 | $1.68 | 183.89K |
| Oct 29, 2026 | $1.82 | $1.89 | $1.745 | $1.75 | 135.95K |
| Oct 28, 2026 | $1.80 | $1.89 | $1.715 | $1.85 | 216.94K |
| Oct 27, 2026 | $1.67 | $1.84 | $1.655 | $1.83 | 342.38K |
| Oct 26, 2026 | $1.91 | $1.96 | $1.64 | $1.70 | 423.01K |
| Oct 23, 2026 | $1.94 | $1.98 | $1.79 | $1.90 | 464.09K |
| Oct 22, 2026 | $1.68 | $1.9699 | $1.67 | $1.94 | 515.85K |
| Oct 21, 2026 | $1.57 | $1.68 | $1.52 | $1.67 | 269.9K |
| Oct 20, 2026 | $1.52 | $1.62 | $1.50 | $1.57 | 275.82K |
| Oct 19, 2026 | $1.57 | $1.595 | $1.44 | $1.55 | 298.13K |
| Oct 16, 2026 | $1.81 | $1.8495 | $1.55 | $1.56 | 333.93K |
| Oct 15, 2026 | $1.78 | $1.86 | $1.7631 | $1.78 | 169.35K |
| Oct 14, 2026 | $1.77 | $1.9101 | $1.75 | $1.79 | 373.27K |
| Oct 13, 2026 | $1.88 | $1.88 | $1.73 | $1.77 | 232.25K |
| Oct 12, 2026 | $1.90 | $1.91 | $1.82 | $1.88 | 164.36K |
| Oct 9, 2026 | $1.83 | $1.92 | $1.785 | $1.89 | 306.2K |
| Oct 8, 2026 | $1.85 | $1.85 | $1.74 | $1.81 | 267.28K |
| Oct 7, 2026 | $1.87 | $1.92 | $1.83 | $1.85 | 138.94K |
| Oct 6, 2026 | $1.90 | $1.96 | $1.86 | $1.88 | 259.1K |
| Oct 5, 2026 | $1.93 | $1.96 | $1.81 | $1.92 | 202.85K |
The latest Smart Investors Daily articles mentioning ELTX.
Company
Market Activity
Research & News
ELTX research
Company profile and research snapshot.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | B. Riley Securities | Buy | — |
| Aug 18, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 16, 2026 | Jones Trading | Hold | — |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 10, 2026 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 29, 2026
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the
Yahoo · Oct 23, 2026
Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P), including patients with and without detectable baseline ctDNA.Encouraging disease-free survival outcomes were observed in both ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients.Baseline prognostic imbalances provide important context for the intent-to-treat results, including a 53% lower risk of recurrence or death with camupepimut (multivariable adjusted HR 0.47; p=0.0086).Integrated clinical and translation
Benzinga · Oct 23, 2026
Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
Benzinga · Oct 23, 2026
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ELTX.
